(27 April 2020) Update on clinical studies of key drug molecules for COVID 19

Update on treatment of COVID-19: ongoing studies between promising and disappointing results.

https://www.ncbi.nlm.nih.gov/pubmed/32335561

A compilation of results of trials going on (up to April 15, 2020)for key molecules used in treatment of COVID-19 is presented. Data for Chloroquine, hydroxychloroquine, remdesevir, favipiravir, lopinavir/ritonavir, tocilizumab, convalescent plasma and immunoglobulins from preliminary studies seem to provide promising results for some of these drugs, some others are giving more disappointing information.